# Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

> **NCT04930887** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 15 (estimated)

## Conditions studied

- Craniofacial Pain
- Migraine
- Cluster Headache
- Trigeminal Autonomic Cephalgia
- Sphenopalatine Ganglion Neuralgia
- Paroxysmal Hemicrania

## Interventions

- **DRUG:** Exparel (Bupivacaine Liposome)
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT04930887
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2028-06
- **Final completion:** 2030-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930887, "Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04930887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*